July marks Disability Pride Month, a time to commemorate the passage of the Americans With Disabilities Act and to celebrate the diversity, resilience, and visibility of the disabled community. This ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...

In a nationwide, retrospective, population-based cohort study, data from the Swedish MS Registry for 7331 patients were analyzed. The adjusted risk of EDSS milestones 3.0, 4.0, and 6.0 were, ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.